Show simple item record

dc.contributor.authorWorboys, Michael; orcid: 0000-0001-8583-7931; email: michael.worboys@manchester.ac.uk
dc.contributor.authorToon, Elizabeth
dc.date.accessioned2021-09-03T15:54:42Z
dc.date.available2021-09-03T15:54:42Z
dc.date.issued2019-11-07
dc.date.submitted2019-01-25
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625774/40656_2019_Article_269.pdf?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625774/40656_2019_Article_269_nlm.xml?sequence=3
dc.identifier.citationHistory and Philosophy of the Life Sciences, volume 41, issue 4, page 54
dc.identifier.urihttp://hdl.handle.net/10034/625774
dc.descriptionFrom Springer Nature via Jisc Publications Router
dc.descriptionHistory: received 2019-01-25, registration 2019-08-01, accepted 2019-08-01, pub-electronic 2019-11-07, online 2019-11-07, pub-print 2019-12
dc.descriptionPublication status: Published
dc.descriptionFunder: Wellcome Trust; doi: http://dx.doi.org/10.13039/100004440; Grant(s): WT 092782
dc.description.abstractAbstract: Cortisone, initially known as ‘compound E’ was the medical sensation of the late 1940s and early 1950s. As early as April 1949, only a week after Philip Hench and colleagues first described the potential of ‘compound E’ at a Mayo Clinic seminar, the New York Times reported the drug’s promise as a ‘modern miracle’ in the treatment of rheumatoid arthritis (RA). Given its high profile, it is unsurprising that historians of medicine have been attracted to study the innovation of cortisone. It arrived at the end of a decade of ‘therapeutic revolutions’, kicked off by penicillin transforming the treatment of bacterial infections and ending with hopes of a revolution in the treatment of non-infectious, chronic inflammatory diseases. Despite these studies of cortisone’s introduction, few historians have taken the story forward and considered how cortisone was adopted and adapted into clinical practice. This article tells the longer of how the drug and its derivatives were taken from research laboratories and integrated into clinical practice; what has in recent decades become known as translational medicine (TM). In exploring cortisone’s first decade in Britain, we focus specifically on its role in the treatment of RA. Our approach is always to consider cortisone’s use in the context of other treatments available to clinicians, and at local and national institutional settings. We do not discuss the many other therapeutic uses of cortisone, which ranged for topical applications for skin diseases to the management of cancers, especially childhood leukaemia, nor do we discuss its close analogue ACTH—AdenoCorticoTropic Hormone. We think there are lessons in our study for TM policies today.
dc.languageen
dc.publisherSpringer International Publishing
dc.rightsLicence for this article: http://creativecommons.org/licenses/by/4.0/
dc.sourcepissn: 0391-9714
dc.sourceeissn: 1742-6316
dc.subjectOriginal Paper
dc.subjectBefore Translational Medicine: Laboratory Clinic Relations
dc.subjectCortisone
dc.subjectTranslational Medicine
dc.subjectRheumatoid arthritis
dc.subjectDrugs industry
dc.subjectDrug innovation
dc.subjectNon-steroidal anti-inflammatory drugs (NSAIDs)
dc.subjectChronic disease
dc.titleSpecial issue—before translational medicine: laboratory clinic relations lost in translation? Cortisone and the treatment of rheumatoid arthritis in Britain, 1950–1960
dc.typearticle
dc.date.updated2021-09-03T15:54:41Z
dc.date.accepted2019-08-01


Files in this item

Thumbnail
Name:
40656_2019_Article_269.pdf
Size:
476.6Kb
Format:
PDF
Thumbnail
Name:
40656_2019_Article_269_nlm.xml
Size:
124.0Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record